Whem will avacopan become generic?

Avacopan (brand name Cibinqi) is a relatively new drug that was first approved by the U.S. Food and Drug Administration (FDA) in 2021 for the treatment of antineutrophil‑cytoplasmic‑antibody‑associated vasculitis (AAV). Because it is a new, brand‑name medication, a generic version will not appear until a few conditions are met:

Putting it together

• Earliest possible generic entry: 2026 (after the 5‑year data exclusivity ends).
• Practical generic entry: Most experts expect the first generic to reach the market between 2028 and 2030, when the key composition‑of‑matter patents expire and any remaining process or use patents are no longer enforceable.

Why the delay

1. Multiple overlapping patents – Avacopan’s patents cover the active ingredient itself, the specific formulation, and the therapeutic indications. These patents tend to expire at different times.
2. Regulatory exclusivity – The FDA’s data exclusivity period (which prohibits generic applications from relying on the brand‑name’s clinical trial data for a set time) ends in 2026, but generics still need to meet all regulatory requirements after that.
3. Market considerations – Even if the legal barriers are cleared, a generic manufacturer must decide to invest in the development and marketing of a new formulation, which can take additional time.

Bottom line

There is no publicly announced date for when a generic version of avacopan will hit the market. The most realistic estimate, based on current patent expirations and regulatory timelines, is somewhere between 2028 and 2030. If you’re waiting for a generic version for insurance or cost‑savings reasons, keep an eye on FDA announcements and the U.S. Patent & Trademark Office’s docket for any changes in the status of avacopan’s patents.